Anika Therapeutics, Inc. (ANIK) Reports Improved Q4 EPS of $0.21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.36 -0.39%
EPS Growth %: +950.0%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: +950.0%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q4 EPS of $0.21, versus $0.10 reported last year. Revenue for the quarter came in at $18.4 million, versus $14.7 million reported last year.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plumas Bancorp (PLBC) Tops Q3 EPS by 15c
- StoneX Reiterates Buy Rating on The Chefs' Warehouse, Inc (CHEF) Ahead of Q3 Earnings
- Solaris Oilfield Infrastructure shares jump on Morgan Stanley upgrade
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
